Preferred Label : PI3K-alpha Inhibitor JS105;
NCIt synonyms : PI3K-a Inhibitor JS105; PI3K Alpha Inhibitor JS105;
NCIt definition : An orally bioavailable inhibitor of the class I phosphatidylinositol-4,5-bisphosphate
3-kinase (PI3K) catalytic subunit alpha (PIK3CA), with potential antineoplastic activity.
Upon oral administration, PI3K-alpha inhibitor JS105 selectively targets, binds to
and inhibits PIK3CA in the PI3K/Akt (protein kinase B)/mammalian target of rapamycin
(mTOR) pathway. This results in apoptosis and growth inhibition in PIK3CA-expressing
tumor cells. By specifically targeting PIK3CA, JS105 may be more efficacious and less
toxic than pan-PI3K inhibitors. Dysregulation of the PI3K/Akt/mTOR pathway is often
found in solid tumors and results in the promotion of tumor cell growth, survival,
and resistance to chemo- and radio-therapy. PIK3CA, one of the most frequently mutated
oncogenes, encodes the p110-alpha catalytic subunit of the class I PI3K.;
Molecule name : JS-105; JS 105;
NCI Metathesaurus CUI : CL1928589;
Origin ID : C206259;
concept_is_in_subset
- has_target
